Abstract: Cellular energy levels in skin cells affected by oxidative stress can be improved through the use of a skin care composition that includes a sucrose ester and a fatty alcohol present at a specific ratio. The fatty alcohol and sucrose ester, when incorporated into a skin care composition at a specific ratio, can provide a synergistic improvement in cellular ATP level for skin cells suffering from the effects of oxidative stress.

Abstract: A composition comprising: a surfactant, an acrylic polymer, chitin or its derivatives, and a metal ion chelating agent. Studies have shown that the composition can promote absorption of effective ingredients in the small intestine and improve their bioavailability.

Abstract: A micronutrient composition is highly effective in treating joint related inflammation and reducing ECM damaging enzymes in joints. The micronutrient composition comprises of Vitamin C, Vitamin E (D-alpha tocopherol), Vitamin B6, Vitamin D3, Folic acid, L-proline, L-lysine, Copper, Betaine HCl, Chondroitin sulfate, N-acetyl-glucosamine, Pycnogenol, SAMe, Cat's claw, Boswellia serrata, Stinging nettle and Glutamine. The micronutrient composition was most effective in supporting critical cellular mechanisms important for healthy joints-increased production and deposition of important ECM components by synovial cells and chondrocytes under pro-inflammatory conditions (presence of LPS). The micronutrient composition also decreased pro-inflammatory IL-6 and decreased secretion of MMP13, the ECM damaging enzyme in joints.

Abstract: A method of preparing personalized supplement packages for a subject involves identifying one or a plurality of suboptimal wellness categories in the subject, rank ordering ingredients in terms of their utility score to the suboptimal conditions, and filling a total package amount with target doses of ingredients added in rank order until the total package amount is filled.

Abstract: The present invention provides a pharmaceutical composition which comprises: (a) an HMG-CoA reductase inhibitor; and (b) cholesterol or a pharmaceutically acceptable precursor thereof; for use in treating Inflammatory Linear Verrucous Epidermal Nevus (ILVEN).

Abstract: Combination of dry extract of Rhodiola, dry extract of Trubulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.

Abstract: The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.

Abstract: A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and colesevelam hydrochloride.

Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.

Abstract: Personal care compositions and methods for treating or preventing lipid peroxidation of skin with the same are disclosed. The personal care composition may include a carrier and a surfactant system present in an effective amount to treat or prevent lipid peroxidation of skin. The surfactant system may include at least one amphoteric surfactant and at least one anionic surfactant. The method may include contacting the personal care composition with the skin and exposing the skin to pollution. Methods for formulation a personal care composition for treating or preventing lipid peroxidation of skin are also disclosed. The method may include determining an oxidation protection factor (OPF) of one or more components, using the OPF to select at least one component of the one or more components, and combining the at least one component of the one or more components with a carrier to form the personal care composition.

Abstract: An absorbent member (20) includes an absorbent sheet (10) in which absorbent polymer (12) is fixed to a base sheet (11) and a cover sheet (21) covering at least a first surface of the absorbent sheet (10). The absorbent sheet (10) has an absorbent polymer fixing proportion of 40% or more. The absorbent member (20) has high fixing performance of the absorbent polymer (12) to the base sheet (11) and is less likely to suffer from detachment of the absorbent polymer (12) even after liquid absorption. The absorbent polymer (12) is preferably fixed to the base sheet (11) with a base sheet fixing adhesive (13) interposed therebetween. The adhesive (13) is preferably an acrylic, silicone-based or rubber-based adhesive, and is preferably a hot-melt adhesive.

Abstract: The present invention relates to a composition, preferably a cosmetic composition, and more preferably a skin cosmetic composition, comprising: (a) at least one complex, comprising at least one cationic polymer and at least one anionic polymer, at least one cationic polymer and at least one amphoteric polymer, at least one anionic polymer and at least one amphoteric polymer, or at least one amphoteric polymer, and at least one non-polymeric acid having two or more pKa values or salt(s) thereof or at least one non-polymeric base having two or more pKb values or salt(s) thereof; (b) at least one oil; and (c) water, wherein the cationic polymer comprises at least one cationic cellulose polymer with at least one fatty chain comprising at least 10 carbon atoms, and if the (a) complex comprises at least one anionic polymer and at least one amphoteric polymer, or at least one amphoteric polymer, the (a) complex further comprises at least one cationic cellulose polymer with at least one fatty chain comprising at leas

Abstract: This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, a pharmaceutically acceptable salt thereof, or a combination therefore that can be administered to a human subject in need thereof in a supine position. The disclosure also provides pharmaceutical compositions which can be administered once-a-day. This disclosure further provides pharmaceutical compositions comprising an extended release composition and providing a delayed release period between about 30 min to about 12 hours.

Abstract: Disclosed are controlled release particles, each controlled release particle of which includes: (a) a core including at least one hydrophobic active material and an emulsifier which is an oil-soluble or oil-dispersible lecithin emulsifier; and (b) a wall at least partially surrounding the core and including an acid insoluble polymer, a colloidal silica, a water insoluble divalent salt, a film forming polymer, and optionally a powder flow aid, wherein the controlled release particle is configured to retain the at least one hydrophobic active material when exposed to an acidic aqueous solution with a pH less than 6, and to release the at least one hydrophobic active material when exposed to a basic aqueous solution with a pH greater than 7. A method for preparing the particles and compositions containing the particles are also disclosed.

Abstract: The present invention provides an artificial dressing and a use of the artificial dressing for promoting wound healing. The artificial dressing includes a gelatin and a fungal extract.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

Abstract: The invention relates to a functional wound dressing being able to detect and indicate the state of the wound, in particular with regard to an infection which is reported to be frequently associated with poorly healing wounds, such as chronic wounds. The present wound dressing can be used in moist wound healing and contains a substance being able to absorb wound exudate from the wound and to provide moisture to the wound.

Abstract: Presented herein are compositions that can be administered to a subject having damaged tissue, for example a wound. The compositions are often administered in combination with administration of energy (e.g., laser energy, light from a light emitting diode, radiofrequency (RF) energy, audio frequency energy, etc.) from an energy generating device and/or system to the affected site. The compositions, systems, devices, and methods herein were found to induce wound healing and tissue regeneration.

Abstract: The invention relates to a functional wound dressing being able to provide substances supporting the healing of a wound to the wound depending on the condition of the wound. In particular, in case of an infection which is reported to be frequently associated with poorly healing wounds, such as chronic wounds, a therapeutic substance is provided to the wound whereas in other cases no therapeutic substance is provided. The present wound dressing can be used in moist wound healing and contains a substance being able to absorb wound exudate from the wound and to provide moisture to the wound.

Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.